NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

West SL, Gartlehner G, Mansfield AJ, et al. Comparative Effectiveness Review Methods: Clinical Heterogeneity [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Sep.

Cover of Comparative Effectiveness Review Methods: Clinical Heterogeneity

Comparative Effectiveness Review Methods: Clinical Heterogeneity [Internet].

Show details

Appendix CEvidence Tables

What is clinical heterogeneity?

Table C1. Guidance documents describing clinical heterogeneity issues

References

1.
Agency for Healthcare Research and Quality. Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews. [Accessed 2007]. Available at http:​//effectivehealthcare​.ahrq.gov/repFiles​/2007_10DraftMethodsGuide.pdf.
2.
Centre for Reviews and Dissemination. Centre for Reviews and Disssemination’s (CRD) Systematic Reviews: Guidance for undertaking reviews in health care. [Accessed March 9, 2009]. Available at http://www​.york.ac.uk​/inst/crd/pdf/Systematic_Reviews.pdf.
3.
The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1. [Accessed 2008]. Available at http:www​.york.ac.uk/inst​/crd/pdf/Systematic_Reviews.pdf.
4.
Project DER. Review methods and report production procedures. [Accessed May 28, 2009]. Available at http://www​.ohsu.edu/ohsuedu​/researchpolicycenter/DERP/
5.
The HuGENet Writing Group. The HuGENETTM HuGE Review Handbook, Version 1.0. [Accessed February 28, 2009]. Available at http://www​.hugenet.ca.
6.
Gesundheitswesen IfQuWi. General methods. [Accessed October 19, 2009]. Available at http://www​.iqwig.de/downloadIQWiG​_General_methods_V-3-0.pdf.
7.
National Health and Medical Research Council. How to review the evidence: systematic identification and review of the scientific literature. [Accessed October 9, 2009]. Available at http://www​.nhmrc.gov​.au/_files_nhmrc/file_publications​/synopses/cp65.pdf.
8.
National Institute for Health and Clinical Excellence. The guidelines manual. [Accessed October 19, 2009]. Available at http://www​.nice.org.uk​/media/5F2/44_The_guidelines​_manual_2009_-_All_chapters​.pdf.
9.
European Network for Health Technology Assessment. HTA core model for medical and surgical interventions 1.0R. [Accessed March 9, 2009]. Available at http://www​.eunethta.net​/upload/WP4/Final%20Deliverables​/HTA%20Core​%20Model%20for​%20Medical%20and%20Surgical​%20Interventions%201%200r.pdf.

Table C2. How have systematic reviews dealt with clinical heterogeneity in the key questions and review process?

Agency for Healthcare Research and Quality (AHRQ) final reports

Cochrane final reports

Database of Abstracts of Reviews of Effects (DARE) final reports

Drug Effectiveness Review Program (DERP) reports

Health Technology Assessment (HTA) final reports

National Institute for Health and Clinical Excellence (NICE)

References

1.
Bruening W, Launders J, Pinkney N, et al. Comparative Effectiveness Review No 2 (Prepared by ECRI Evidence-based Practice Center under Contract No 290-02-0019) Rockville, MD: Agency for Healthcare Research and Quality; 2006. Effectiveness of noninvasive diagnostic tests for breast abnormalities. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
2.
Seidenfeld J, Samson DJ, Bonnell CJ, et al. Management of small cell lung cancer, Evidence Report/Technology Assessment No. 143. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026.) AHRQ Publication No. 06-E016. Rockville, MD: Agency for Healthcare Research and Quality; 2006.
3.
Wilt TJ, Shamliyan T, Taylor B, et al. Comparative Effectiveness Review No 13 (Prepared by Minnesota Evidence-based Practice Center under Contract No 290-02-0009) Rockville, MD: Agency for Healthcare Research and Quality; 2008. Comparative effectiveness of therapies for clinically localized prostate cancer. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
4.
Shekelle P, Rich M, Morton S, et al. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness, Evidence Report/Technology Assessment No. 82 (Prepared by the Southern California-RAND Evidence-based Practice Center under Contract No 290-97-0001). AHRQ Publication No. 03-E045. Rockville, MD: Agency for Healthcare Research and Quality; Jul, 2003.
5.
Viswanathan M, Visco AG, Hartmann K, et al. Cesarean delivery on maternal request, Evidence Report/Technology Assessment No. 133. AHRQ Pub. No. 06-E009. Rockville, MD: Agency for Healthcare Research and Quality; 2006. [PMC free article: PMC4781381] [PubMed: 17627329]
6.
Wilt TJND, Kim C-B, Kane RL, Linabery A, Tacklind J, MacDonald R, Rutks I. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evidence Report/Technology Assessment No. 121 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.) AHRQ Publication No. 05-E017-2. Rockville, MD. Agency for Healthcare Research and Quality. 2005
7.
Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness Review No 7 (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No 290-02-0016) Rockville, MD: Agency for Healthcare Research and Quality; Jan, 2007. 2007. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
8.
Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness Review No 1 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No 290-02-0022) Rockville, MD: Agency for Healthcare Research and Quality; Dec, 2005. 2005. Comparative effectiveness of management strategies for gastroesophageal reflux disease. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
9.
Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveness Review No 10 (Prepared by Duke Evidence-based Practice Center under Contract No 290-02-0025) Rockville, MD: Agency for Healthcare Research and Quality; 2007. Comparative effectiveness of angiotensin-converting enzyme Inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
10.
Caughey AB, Sundaram V, Kaimal AJ, et al. Maternal and neonatal outcomes of elective induction of labor, Evidence Report/Technology Assessment No. 176. (Prepared by the Stanford University-UCSF Evidenced-based Practice Center under contract No. 290-02-0017.) AHRQ Publication No. 09-E005. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
11.
Chou R, Helfand M, Peterson K, et al. Comparative Effectiveness Review No 4 (Prepared by the Oregon Evidence-based Practice Center under Contract No 290-02-0024) Rockville, MD: Agency for Healthcare Research and Quality; Sep, 2006. 2006. Comparative effectiveness and safety of analgesics for osteoarthritis. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
12.
Zhang M, Liu X, Li J, et al. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007. [PubMed: 17443560]
13.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;365(9472):1687–717. [PubMed: 15894097]
14.
Amarasena IU, Walters JAE, Wood-Baker R, et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews: Reviews. 2008;(4) [PubMed: 18843733]
15.
Cardona Zorrilla AF, Reveiz L, Ospina Edgar G, et al. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews: Reviews. 2008;(2) [PubMed: 18425900]
16.
Dong R, Chen X, Wu T, et al. Elemene for the treatment of lung cancer, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
17.
Shelley M, Wilt T, Coles B, et al. Cryotherapy for localised prostate cancer, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007. [PubMed: 17636783]
18.
De Conti P, Atallah Álvaro N, Arruda Homero O, et al. Intermittent versus continuous androgen suppression for prostatic cancer, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
19.
Frobel A-K, Hulpke-Wette M, Schmidt Klaus G, et al. Beta-blockers for congestive heart failure in children, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009.
20.
Mathai M, Hofmeyr GJ. Abdominal surgical incisions for caesarean section, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
21.
Anorlu RI, Maholwana B, Hofmeyr GJ. Methods of delivering the placenta at caesarean section, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008. [PubMed: 18646109]
22.
Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009. [PubMed: 19370693]
23.
Roderick PJ, Willis NS, Blakeley S, et al. Correction of chronic metabolic acidosis for chronic kidney disease patients, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007. [PubMed: 17253467]
24.
Effing T, Monninkhof EM, van der Valk P, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Reviews. 2007;(4) [PubMed: 17943778]
25.
Puhan M, Scharplatz M, Troosters T, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: Reviews. 2009;(1) [PubMed: 19160250]
26.
Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respiratory Research. 2007;8:30. [PMC free article: PMC1853091] [PubMed: 17407610]
27.
Yang IA, Fong K, Sim EHA, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
28.
Nieuwenhuijsen K, Bültmann U, Neumeyer-Gromen A, et al. Interventions to improve occupational health in depressed people, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008. [PubMed: 18425942]
29.
Morriss R, Faizal Mohammad A, Jones Ashley P, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007. [PubMed: 17253526]
30.
Hackett ML, Anderson CS, House A, et al. Interventions for preventing depression after stroke, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008.
31.
Furtado Vivek A, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008.
32.
Cipriani A, Rendell Jennifer M, Geddes J. Olanzapine in long-term treatment for bipolar disorder, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009. [PubMed: 19160237]
33.
Liu Jian P, Yang H, Xia Y, et al. Herbal preparations for uterine fibroids, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009. [PMC free article: PMC3155698] [PubMed: 19370619]
34.
Beaumont HH, Augood C, Duckitt K, et al. Danazol for heavy menstrual bleeding, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
35.
Lethaby A, Augood C, Duckitt K, et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007. [PubMed: 17943741]
36.
Lethaby A, Irvine Gill A, Cameron Iain T. Cyclical progestogens for heavy menstrual bleeding, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008.
37.
Wiysonge C, Shey U, Bradley HA, et al. Beta-blockers for hypertension, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
38.
Woolf SH, Battista RN, Anderson GM, et al. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol. 1990;43(9):891–905. [PubMed: 2145399]
39.
Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007(1):CD002252. [PubMed: 17253478]
40.
Zijdenbos IL, de Wit Niek J, van der Heijden GJ, et al. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database of Systematic Reviews: Reviews. 2009;(1) [PubMed: 19160286]
41.
Webb AN, Kukuruzovic R, Catto-Smith AG, et al. Hypnotherapy for treatment of irritable bowel syndrome, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
42.
Evans Beti W, Clark Wendy K, Moore David J, et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database of Systematic Reviews: Reviews. 2007;(4) [PubMed: 17943807]
43.
Smyth R, Alldred SK, Markham C. Amniotomy for shortening spontaneous labour, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007. [PubMed: 17943891]
44.
Boulvain M, Kelly Anthony J, Irion O. Intracervical prostaglandins for induction of labour. Cochrane Database of Systematic Reviews: Reviews. 2008;(1) [PubMed: 18254122]
45.
Li J, Zhang Q, Zhang M, et al. Intravenous magnesium for acute myocardial infarction, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2007.
46.
Magee K, Campbell Samuel G, Moher D, et al. Heparin versus placebo for acute coronary syndromes, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008. [PubMed: 18425889]
47.
Wu T, Ni J, Wei J. Danshen (Chinese medicinal herb) preparations for acute myocardial infarction, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008. [PubMed: 18425903]
48.
Brouwer RW, van Raaij TM, Bierma-Zeinstra SMA, et al. Osteotomy for treating knee osteoarthritis. Cochrane Database of Systematic Reviews: Reviews. 2007;(3) [PubMed: 17636743]
49.
Fransen M, McConnell S. Exercise for osteoarthritis of the knee, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008.
50.
Laupattarakasem W, Laopaiboon M, Laupattarakasem P, et al. Arthroscopic debridement for knee osteoarthritis, Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008.
51.
Boutin DL. Effectiveness of cognitive behavioral and supportive-expressive group therapy for women diagnosed with breast cancer: a review of the literature. Journal for Specialists in Group Work. 2007;32(3):267–284.
52.
van der Ploeg IM, van Esser S, van den Bosch MA, et al. Radiofrequency ablation for breast cancer: a review of the literature. European Journal of Surgical Oncology. 2007;33(6):673–677. [PubMed: 17369003]
53.
Yau G, Lock M, Rodrigues G. Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer. 2007;58(2):161–170. [PubMed: 17723250]
54.
Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: a systematic review and metaanalysis. Chest. 2007;131(2):539–548. [PubMed: 17296659]
55.
Coory M, Gkolia P, Yang IA, et al. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer. 2008;60(1):14–21. [PubMed: 18304687]
56.
Tarnhuvud M, Wandel C, Willman A. Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review. European Journal of Oncology Nursing. 2007;11(4):328–339. [PubMed: 17409023]
57.
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–1136. [PubMed: 17905165]
58.
Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. European Heart Journal. 2007;28(4):457–462. [PubMed: 17289748]
59.
Roberts F, Ryan GJ. The safety of metformin in heart failure. Annals of Pharmacotherapy. 2007;41(4):642–646. [PubMed: 17374622]
60.
Nicholson WK, Wilson LM, Witkop CT, et al. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. Report. 2008;96 [PMC free article: PMC4781072] [PubMed: 18457474]
61.
Press JZ, Klein MC, Kaczorowski J, et al. Does cesarean section reduce postpartum urinary incontinence: a systematic review. Birth. 2007;34(3):228–237. [PubMed: 17718873]
62.
Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. American Heart Journal. 2008;155(5):791–805. [PubMed: 18440325]
63.
Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–651. [PMC free article: PMC2270960] [PubMed: 18299289]
64.
Bradley-Drummond M, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416. [PMC free article: PMC4804462] [PubMed: 19033591]
65.
Niesink A, Trappenburg JC, de Weertvan Oene GH, et al. Systematic review of the effects of chronic disease management on quality-of-life in people with chronic obstructive pulmonary disease. Respiratory Medicine. 2007;101(11):2233–2239. [PubMed: 17804213]
66.
Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2008;133(3):756–766. [PubMed: 18321904]
67.
Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–50. [PubMed: 18812535]
68.
Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clinical Therapeutics. 2008;30(8):1416–1425. [PubMed: 18803985]
69.
Usala T, Clavenna A, Zuddas A, et al. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. European Neuropsychopharmacology. 2008;18(1):62–73. [PubMed: 17662579]
70.
Cuijpers P, Brannmark JG, van Straten A. Psychological treatment of postpartum depression: a meta-analysis. Journal of Clinical Psychology. 2008;64(1):103–118. [PubMed: 18161036]
71.
Chin AM. Clinical effects of reminiscence therapy in older adults: a meta-analysis of controlled trials. Hong Kong Journal of Occupational Therapy. 2007;17(1):10–22.
72.
Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. Canadian Medical Association Journal. 2008;178(3):296–305. [PMC free article: PMC2211353] [PubMed: 18227449]
73.
Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. Journal of Gastroenterology and Hepatology. 2007;22(3):304–310. [PubMed: 17295758]
74.
Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter. 2007;12(5):541–546. [PubMed: 17760723]
75.
Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clinical Gastroenterology and Hepatology. 2007;5(2):178–185. [PubMed: 17174612]
76.
Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Archives of Internal Medicine. 2008;168(6):571–580. [PubMed: 18362248]
77.
Connell P, Wolfe C, McKevitt C. Preventing stroke: a narrative review of community interventions for improving hypertension control in black adults. Health and Social Care in the Community. 2008;16(2):165–187. [PubMed: 18290982]
78.
Ford AC, Talley NJ, Velhuyzen van Zenten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA. 2008;300(15):1793–1805. [PubMed: 18854541]
79.
Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. [PMC free article: PMC2583392] [PubMed: 19008265]
80.
Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome. Archives of Internal Medicine. 2009;169(7):651–658. [PubMed: 19364994]
81.
Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Archives of Medical Science. 2008;4(1):71–76.
82.
Baker WL, Couch KA. Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. American Journal of Health-System Pharmacy. 2007;64(8):830–836. [PubMed: 17420199]
83.
Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. American Heart Journal. 2007;154(6):1065–1071. [PubMed: 18035076]
84.
Sinno MC, Khanal S, Al-Mallah MH, et al. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. American Heart Journal. 2007;153(4):579–586. [PubMed: 17383297]
85.
Christensen R, Bartels EM, Astrup A, et al. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis and Cartilage. 2008;16(4):399–408. [PubMed: 18042410]
86.
Minns Lowe CJ, Barker KL, Dewey M, et al. Effectiveness of physiotherapy exercise after knee arthroplasty for osteoarthritis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;335:812. [PMC free article: PMC2034713] [PubMed: 17884861]
87.
Pisters MF, Veenhof C, van Meeteren NL, et al. Long-term effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review. Arthritis and Rheumatism. 2007;57(7):1245–1253. [PubMed: 17907210]
88.
Chou R, Helfand M, Carson S. Drug class review on angiotensin converting enzyme inhibitors. Final Report. Portland, OR: Oregon Health & Science University; 2005.
89.
Furmaga E, Glassman P, Rhodes S, et al. Drug class review on angiotensin II receptor antagonists. Final report. Portland, OR: Oregon Health & Science University; 2006.
90.
Helfand M, Peterson K, Christensen V, et al. Drug class review on beta adrenergic blockers. Final report update 4. Portland, OR: Oregon Health & Science University; 2009.
91.
Jonas DE, Kiser K, Shilliday BB, et al. Drug class review on controller medications for asthma. Portland, OR: Oregon Health & Science University; 2008.
92.
Hansen RA, Gartlehner G, Lohr KN, et al. Drug class review on inhaled corticosteroids. Final report update 1. Portland, OR: Oregon Health & Science University; 2006. [PubMed: 20496414]
93.
Gartlehner G, Morgan LC, Thieda P, et al. Drug class review second generation antidepressants. Final report update 4. Portland, OR: Oregon Health & Science University; 2008.
94.
McDonagh MS, Carson S, Thakurta S. Drug class review on proton pump inhibitors. Final report update 5. Portland, OR: Oregon Health & Science University; 2009.
95.
McDonagh MS, Eden KB, Peterson K. Drug class review on calcium channel blockers. Final report. Portland, OR: Oregon Health & Science University; 2005. [PubMed: 20496186]
96.
Gartlehner G, Jonas DE, Morgan LC, et al. Drug class review on constipation drugs. Final report. Portland, OR: Oregon Health & Science University; 2007. [PubMed: 20496364]
97.
Dailey JH, Glassman P, McDonagh M, et al. Drug class review on newer antiplatelet agents. Final report update 1. Portland, OR: Oregon Health & Science University; 2007. [PubMed: 20495616]
98.
Helfand M, Carson S, Kelley C. Drug class review on HMG-CoA reductase inhibitors (statins). Final report. Portland, OR: Oregon Health & Science University; 2006. [PubMed: 20496454]
99.
Chou R, Helfand M, Peterson K, et al. Drug class review on cyclo-oxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs). Final report update 3. Portland, OR: Oregon Health & Science University; 2006. [PubMed: 20496448]
100.
Adelaide Health, Technology A. Digital mammography for breast cancer screening and diagnosis. Adelaide: Adelaide Health Technology Assessment (AHTA); 2008.
101.
Korencan A, Felder-Puig R, Guba B, et al. Testing for HER2 positive breast cancer, Challenge for improvement of current conditions and practice. Wien: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA); 2007.
102.
Dunfield L, Severn M. Effectiveness of magnetic resonance imaging (MRI) screening for women at high risk of breast cancer. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007.
103.
Adelaide Health Technology Assessment on behalf of National Horizon Scanning U. Genetic Screening for Lung Cancer utilising CT; horizon scanning prioritizing summary. Vol. 15. Adelaide: Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC); 2007.
104.
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen. Interstitial brachytherapy in localised prostate cancer. Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2007.
105.
Pearson SD, Ladapo J, Prosser L. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. Boston: Institute for Clinical and Economic Review (ICER); 2007.
106.
Swedish Council on Technology Assessment in Health C. Light therapy for depression, and other treatment of seasonal affective disorder. Stockholm: Swedish Council on Technology Assessment in Health Care (SBU); 2007.
107.
Swedish Council on Technology Assessment in Health C. Computer-based cognitive behavioral therapy for anxiety disorders or depression - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU); 2007.
108.
McLoughlin DM, Mogg A, Eranti S, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess. 2007 Jul;11(24):1–54. [PubMed: 17580003]
109.
Screening for postnatal depression within the Well Child Tamariki Ora Framework. Christchurch: Health Services Assessment Collaboration (HSAC); 2008.
110.
Swedish Council on Technology Assessment in Health C. Dyspepsia and gastro-oesophageal reflux. Stockholm: Swedish Council on Technology Assessment in Health Care (SBU); 2007.
111.
Hermanowski T, Kowalik E, Jakubczyk M, et al. Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis. Warsaw: Agency for Health Technology Assessment in Poland (AHTAPol); 2007.
112.
Hermanowski T, Kowalik E, Jakubczyk M, et al. Treatment of pulmonary arterial hypertension in Poland - current practice. Survey results. Warsaw: Agency for Health Technology Assessment in Poland (AHTAPol); 2007.
113.
Tran K, Ho C, Noorani HZ, et al. Overview of thiazide diuretics as first-line treatment for hypertension [Technology overview number 34] Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
114.
Comparison of efficacy, effectiveness and safety of fibrinolysis and primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2008.
115.
National Coordinating Centre for Health Technology Assessment. The Birmingham Rehabilitation Uptake Maximisation Study (BRUM), Home-based compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence. 2007. [PubMed: 17767899]
116.
National Institute for Health and Clinical Excellence. Secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Institute for Health and Clinical Excellence (NICE); 2007.
117.
Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid (viscosupplementation) for hip osteoarthritis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007.
118.
Samson DJ, Grant MD, Ratko TA, et al. Treatment of primary and secondary osteoarthritis of the knee. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2007. [PMC free article: PMC4781439] [PubMed: 18088162]
119.
National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care. Rushden, Northamptsonshire: The British Psychological Society and Gaskell; 2004.
120.
North of England Dyspepsia Guideline Development Group. Dyspepsia: managing dyspepsia in adults in primary care. Report (112) Newcastle upon Tyne (UK): Centre for Health Services Research School of Population and Health Sciences University of Newcastle upon Tyne; 2004.
121.
Cooper A, Skinner J, Nherera L, et al. Clinical guidelines and evidence review for post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2007.
122.
National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guideline for care and management in adults. London: Royal College of Physicians; 2008. [PubMed: 21290638]
123.
National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment NICE Clinical Guideline. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009. p. 37.

What are critiques in how systematic reviews handle clinical heterogeneity? What evidence is there to support how to best address clinical heterogeneity in a systematic review?

Table C3. Summary of methodologic publications regarding clinical heterogeneity

References

1.
Adams KFJ. Post hoc subgroup analysis and the truth of a clinical trial [editorial] American Heart Journal. 1998 Nov;136(5):753–758. [PubMed: 9812066]
2.
Anello C, Fleiss JL. Exploratory or analytic meta-analysis: should we distinguish between them. J Clin Epidemiol. 1995 Jan;48(1:):109–116. discussion 17–18. [PubMed: 7853037]
3.
Bailar 3rd JC. The practice of meta-analysis. J Clin Epidemiol. 1995 Jan;48(1):149–157. [PubMed: 7853040]
4.
Bailey KR. Inter-study differences: how should they influence the interpretation and analysis of results. Stat Med. 1987 04–05;6(3):351–360. [PubMed: 3616288]
5.
Barza M, Trikalinos TA, Lau J. Statistical considerations in meta-analysis. Infectious Disease Clinics of North America. 2009 Jun;23(2:):195–210. Table of Contents. [PubMed: 19393905]
6.
Baujat B, Mahe C, Pignon JP, et al. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002 Sep 30;21(18):2641–2652. [PubMed: 12228882]
7.
Bellinger DC. Effect modification in epidemiologic studies of low-level neurotoxicant exposures and health outcomes. 2000:133–140. [PubMed: 10642122]
8.
Berlin JA. Invited commentary: benefits of heterogeneity in meta-analysis of data from epidemiologic studies. Am J Epidemiol. 1995 Aug;142(4):383–387. [PubMed: 7625402]
9.
Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA. 1999 Mar 3;281(9):830–834. [PubMed: 10071005]
10.
Berlin JA, Santanna J, Schmid CH, et al. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med. 2002 Feb 15;21(3):371–387. [PubMed: 11813224]
11.
Berry DA. Subgroup analyses [letter] Biometrics. 1990 Dec;46(4):1227–1230. [PubMed: 2085637]
12.
Bigger JT. Issues in subgroup analyses and meta-analyses of clinical trials. J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S6–S8. [PubMed: 12950510]
13.
Blettner M, Sauerbrei W, Schlehofer B, et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. International Journal of Epidemiology. 1999 Feb;28(1):1–9. [PubMed: 10195657]
14.
Brand R, Kragt H. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med. 1992 Dec;11(16):2077–2082. [PubMed: 1293669]
15.
Brookes ST, Whitely E, Egger M, et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology. 2004 Mar;57(3):229–236. [PubMed: 15066682]
16.
Brookes ST, Whitley E, Peters TJ, et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment. 2001;5(33):1–56. [PubMed: 11701102]
17.
Chalmers TC. Problems induced by meta-analyses. Stat Med. 1991 Jun;10(6:):971–979. discussion 9–80. [PubMed: 1876787]
18.
Chalmers TC, Lau J. Changes in clinical trials mandated by the advent of meta-analysis. Stat Med. 1996 Jun 30;15(12:):1263–1268. discussion 9–72. [PubMed: 8817800]
19.
Colditz GA, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol. 1995 Aug 15;142(4):371–382. [PubMed: 7625401]
20.
Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol. 1995 Jan;48(1):167–171. [PubMed: 7853043]
21.
Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Annals of Internal Medicine. 1997 Sep;127(5):380–387. [PubMed: 9273830]
22.
Delgado-Rodriguez M. Systematic reviews of meta-analyses: applications and limitations. Journal of Epidemiology and Community Health. 2006 Feb;60(2):90–92. [PMC free article: PMC2566156] [PubMed: 16415253]
23.
Dickersin K, Berlin JA. Meta-analysis: state-of-the-science Epidemiologic Reviews. 1992;14:154–176. [PubMed: 1289110]
24.
Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Stat Med. 2002 Oct 15;21(19):2971–2980. [PubMed: 12325113]
25.
Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med. 2000 Jul 15;19(13):1707–1728. [PubMed: 10861773]
26.
Eysenck HJ. Meta-analysis and its problems. BMJ. 1994 Sep 24;309(6957):789–792. [PMC free article: PMC2541015] [PubMed: 7950571]
27.
Feinstein AR. The problem of cogent subgroups: a clinicostatistical tragedy [comment] Journal of Clinical Epidemiology. 1998 Apr;51(4):297–299. [PubMed: 9539884]
28.
Feinstein AR. Meta-analysis and meta-analytic monitoring of clinical trials. Stat Med. 1996 Jun 30;15(12:):1273–1280. discussion 81–83. [PubMed: 8817801]
29.
Fletcher RH. Evaluation of interventions. J Clin Epidemiol. 2002 Dec;55(12):1183–1190. [PubMed: 12547447]
30.
Freemantle N, Mason J, Eccles M. Deriving treatment recommendations from evidence within randomized trials - The role and limitation of meta-analysis. International Journal of Technology Assessment in Health Care. 1999 Sep;15(2):304–315. [PubMed: 10507190]
31.
Gerritsen AAM, de Vet HCW, Scholten R, et al. Enabling meta-analysis in systematic reviews on carpal tunnel syndrome. Journal of Hand Surgery-American Volume. 2002 Sep;27A(5):828–832. [PubMed: 12239672]
32.
Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002 Jun 15;21(11):1503–1511. [PubMed: 12111916]
33.
Greenland S, O'Rourke K. Meta-Analysis. Modern Epidemiology. 3rd ed. Rothman KJ, Greenland S, Lash TL, editors. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. pp. 652–682.
34.
Hahn S, Williamson PR, Hutton JL, et al. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med. 2000 Dec 30;19(24):3325–3336. [PubMed: 11122498]
35.
Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Statistics in Medicine. 1998 Apr;17(8):841–856. [PubMed: 9595615]
36.
Higgins J, Thompson S, Deeks J, et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. Journal of Health Services Research & Policy. 2002 Jan;7(1):51–61. [PubMed: 11822262]
37.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–560. [PMC free article: PMC192859] [PubMed: 12958120]
38.
Horwitz RI. Complexity and contradiction in clinical trial research. The American Journal of Medicine. 1987 Mar;82(3):498–510. [PubMed: 3548349]
39.
Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335(7626):914–916. [PMC free article: PMC2048840] [PubMed: 17974687]
40.
Ioannidis JP, Lau J. The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol. 1997 Oct;50(10):1089–1098. [PubMed: 9368516]
41.
Ioannidis JP, Lau J. Uncontrolled pearls, controlled evidence, meta-analysis and the individual patient. J Clin Epidemiol. 1998 Aug;51(8):709–711. [PubMed: 9743320]
42.
Ioannidis JP, Trikalinos TA, Zintzaras E. Extreme between-study homogeneity in meta-analyses could offer useful insights. J Clin Epidemiol. 2006 Oct;59(10):1023–1032. [PubMed: 16980141]
43.
Koopman L, van der Heijden GJ, Glasziou PP, et al. A systematic review of analytical methods used to study subgroups in (individual patient data) meta-analyses. J Clin Epidemiol. 2007 Oct;60(10):1002–1009. [PubMed: 17884593]
44.
Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661–687. [PMC free article: PMC2690188] [PubMed: 15595946]
45.
Lambert PC, Sutton AJ, Abrams KR, et al. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol. 2002 Jan;55(1):86–94. [PubMed: 11781126]
46.
Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997 Nov 1;127(9):820–826. [PubMed: 9382404]
47.
Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998 Jan 10;351(9096):123–127. [PubMed: 9439507]
48.
Lecky FE, Little RA, Brennan P. The use and misuse of meta-analysis. Journal of Accident & Emergency Medicine. 1996 Nov;13(6):373–378. [PMC free article: PMC1342799] [PubMed: 8947790]
49.
Liberati A. "Meta-analysis: statistical alchemy for the 21st century": discussion. A plea for a more balanced view of meta-analysis and systematic overviews of the effect of health care interventions. J Clin Epidemiol. 1995 Jan;48(1):81–86. [PubMed: 7853051]
50.
Macarthur C, Foran PJ, Bailar 3rd JC. Qualitative assessment of studies included in a meta-analysis: DES and the risk of pregnancy loss. J Clin Epidemiol. 1995 Jun;48(6):739–747. [PubMed: 7769404]
51.
Maguire MJ, Hemming K, Hutton JL, et al. Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies. Epilepsy Research. 2008 Aug;80(2–3):201–212. [PubMed: 18515046]
52.
Messori A. Current controversies in the application of meta-analysis (with special reference to oncological treatments) Pharmacy World & Science. 1997 Jun;19(3):152–158. [PubMed: 9259031]
53.
Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Onkologie. 2000 Dec;23(6):597–602. [PubMed: 11441269]
54.
Moher D, Jadad AR, Klassen TP. Guides for reading and interpreting systematic reviews- III. How did the authors synthesize the data and make their conclusions? Archives of Pediatrics & Adolescent Medicine. 1998 Sep;152(9):915–920. [PubMed: 9743039]
55.
Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis) Annual Review of Public Health. 1996;17:1–23. [PubMed: 8724213]
56.
Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992 Jan 1;116(1):78–84. [PubMed: 1530753]
57.
Patsopoulos NA, Evangelou E, Ioannidis JP. Heterogeneous views on heterogeneity. International Journal of Epidemiology. 2008 Oct 21 [PMC free article: PMC4719167] [PubMed: 18940836]
58.
Petitti DB. Meta-analysis and endocrinology. Endocrinology and Metabolism Clinics of North America. 1997 Mar;26(1):31–37. [PubMed: 9074851]
59.
Petitti DB. Approaches to heterogeneity in meta-analysis. Statistics in Medicine. 2001 Dec;20(23):3625–3633. [PubMed: 11746342]
60.
Reade MC, Delaney A, Bailey MJ, et al. Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. Critical Care. 2008;12(4):220. [PMC free article: PMC2575558] [PubMed: 18671838]
61.
Riley RD, Dodd SR, Craig JV, et al. Meta-analysis of diagnostic test studies using individual patient data and aggregate data. Statistics in Medicine. 2008 Dec;27(29):6111–6136. [PubMed: 18816508]
62.
Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1–7;365(9453):82–93. [PubMed: 15639683]
63.
Santaguida PL, Helfand M, Raina P. Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Annals of Internal Medicine. 2005 Jun 21;142(12 Pt 2):1066–1072. [PubMed: 15968031]
64.
Sauerland S, Seiler CM. Role of systematic reviews and meta-analysis in evidence-based medicine. World Journal of Surgery. 2005 May;29(5):582–587. [PubMed: 15827839]
65.
Schmid CH, Lau J, McIntosh MW, et al. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998 Sep 15;17(17):1923–1942. [PubMed: 9777687]
66.
Schmid CH, Stark PC, Berlin JA, et al. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. Journal of Clinical Epidemiology. 2004 Jul;57(7):683–697. [PubMed: 15358396]
67.
Schmid CH. Exploring heterogeneity in randomized trials via meta-analysis. Drug Information Journal. 1999;33:211–224.
68.
Simmonds MC, Higgins JP, Stewart LA, et al. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials. 2005;2(3):209–217. [PubMed: 16279144]
69.
Smith GD, Egger M. Going beyond the grand mean: subgroup analysis in meta-analysis of randomised trials [book chapter] Systematic Review in Health Care: Meta-analysis in Context. 2nd ed. Egger M, Smith GD, Altman DG, editors. London, England: BMJ Publishing Group; 2001. pp. 143–156.
70.
Smith CT, Williamson PR, Marson AG. An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. Journal of Evaluation in Clinical Practice. 2005 Oct;11(5):468–478. [PubMed: 16164588]
71.
Song FJ, Sheldon TA, Sutton AJ, et al. Methods for exploring heterogeneity in meta-analysis. Evaluation & the Health Professions. 2001 Jun;24(2):126–151. [PubMed: 11523383]
72.
Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med. 2008 Feb 28;27(5):625–650. [PubMed: 17590884]
73.
Thacker SB, Peterson HB, Stroup DF. Metaanalysis for the obstetrician-gynecologist. American Journal of Obstetrics and Gynecology. 1996 May;174(5):1403–1407. [PubMed: 9065103]
74.
Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994 Nov 19;309(6965):1351–1355. [PMC free article: PMC2541868] [PubMed: 7866085]
75.
Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002 Jun 15;21(11):1559–1573. [PubMed: 12111920]
76.
Thompson SG, Higgins JP. Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit. Lancet. 2005 Jan 22–28;365(9456):341–346. [PubMed: 15664231]
77.
Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet. 1991 Nov 2;338(8775):1127–1130. [PubMed: 1682553]
78.
Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: A comparison of methods. Statistics in Medicine. 1999 Oct;18(20):2693–2708. [PubMed: 10521860]
79.
Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Statistical Methods in Medical Research. 2001 Dec;10(6):375–392. [PubMed: 11763548]
80.
Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet. 1995 Mar 25;345(8952):772–776. [PubMed: 7891492]
81.
Weed DL. Interpreting epidemiological evidence: how meta-analysis and causal inference methods are related. International Journal of Epidemiology. 2000 Jun;29(3):387–390. [PubMed: 10869307]
82.
Winegardner ML, Reaume KT, Dabaja GS, et al. Practical application of nonrandomized research to patient care: A case study of nesiritide. Pharmacotherapy. 2007 Jan;27(1):143–151. [PubMed: 17192168]
83.
Xu HR, Platt RW, Luo ZC, et al. Exploring heterogeneity in meta–analyses: needs, resources and challenges. 2008;2008:18–28. [PubMed: 18237348]

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...